Mycobacterial infectious disease
MONDO:0020590Infection due to organisms from the genus Mycobacteria.
Also known as: mycobacterial infection, mycobacteriosis, mycobacterium infection
361 clinical trials for this condition and its sub-types, 23 tagged with Mycobacterial infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mycobacterial infectious disease
-
Tuberculosis 218 trials · 299 incl. sub-types
12 sub-types
- Pulmonary tuberculosis 108 trials · 111 incl. sub-types Sub-types →
- Latent tuberculosis infection 72 trials
- Drug-resistant tuberculosis 9 trials · 40 incl. sub-types Sub-types →
- Extrapulmonary tuberculosis 6 trials · 28 incl. sub-types Sub-types →
- Active tuberculosis 23 trials
- Tuberculous encephalopathy 1 trial
- Endocrine tuberculosis 0 trials Sub-types →
- Multifocal tuberculosis 0 trials
- Primary bone and joint tuberculosis 0 trials
- Primary tuberculosis of the digestive system 0 trials
- Primary tuberculous lymphadenitis 0 trials
- Tuberculoma 0 trials
-
Mycobacterium avium complex disease 22 trials
-
Leprosy 11 trials · 12 incl. sub-types
6 sub-types
- Lepromatous leprosy 3 trials
- Multibacillary leprosy 3 trials
- Borderline leprosy 0 trials
- Indeterminate leprosy 0 trials
- Paucibacillary leprosy 0 trials
- Tuberculoid leprosy 0 trials
-
Buruli ulcer disease 3 trials
-
Mycobacterium xenopi infection 2 trials
-
Aquarium granuloma 0 trials
Most studied deeper sub-types
-
New drug candidate takes on stubborn lung infection
Disease control CompletedThis study tests whether adding delpazolid to standard treatment can reduce bacterial levels in people with hard-to-treat Mycobacterium abscessus lung infections. Participants take delpazolid tablets daily for 12 weeks, with the option to continue up to one year if there is clini…
Phase 2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could fewer antibiotics be better for MAC lung disease?
Disease control CompletedThis study tested whether taking two antibiotics instead of three is just as effective for treating a lung infection called MAC, while causing fewer side effects. 474 adults with MAC lung disease were randomly assigned to receive either two or three drugs for 12 months. The goal …
Phase 2/3 • Sponsor: Kevin Winthrop • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Inhaled antibiotic shows promise against stubborn lung infection
Disease control CompletedThis study tested whether adding an inhaled antibiotic (ALIS) to standard oral antibiotics helps adults with a new diagnosis of a hard-to-treat lung infection caused by MAC bacteria. About 425 adults took part. The main goal was to see if the combination improved breathing sympto…
Phase 3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Which antibiotic wins against this tough lung bug?
Disease control CompletedThis study tested two different antibiotics—clarithromycin or moxifloxacin—alongside standard drugs to treat a rare lung infection caused by M. xenopi bacteria. Researchers tracked whether patients' sputum samples became bacteria-free after 6 months. The goal was to find the more…
Phase 3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Scientists compare sputum collection methods to improve diagnosis of lung infection
Knowledge-focused CompletedThis study looked at different ways to collect sputum (phlegm) from people with a lung infection called nontuberculous mycobacterial (NTM) infection. The goal was to see which method gives the best samples for diagnosing and understanding the infection. Participants provided thro…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
NIH study aims to unlock secrets of lung mucus diseases
Knowledge-focused CompletedThis completed study looked at people with genetic conditions that affect how the lungs clear mucus, such as cystic fibrosis and primary ciliary dyskinesia. Researchers examined 87 participants, including healthy volunteers, to understand why these patients get repeated lung infe…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Cancer patients face more treatment side effects from rare lung infections
Knowledge-focused CompletedThis study examined 41 patients treated for non-tuberculous mycobacteria (NTM) infections, comparing those with and without cancer. The goal was to count side effects from NTM treatment in each group to understand why cancer patients often stop therapy. Researchers hope this will…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC